We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assays Evaluated for Influenza in Blood Donors

By LabMedica International staff writers
Posted on 26 Mar 2012
Print article
Sensitive molecular assays have been used to screen blood donors for the presence of influenza viremia via ribonucleic acid (RNA) testing.

Several influenza RNA amplification assays, including transcription-mediated amplification (TMA) and two reverse-transcription polymerase chain reaction (RT-PCR) assays were evaluated and used to test donor samples.

Scientists at the Blood Systems Research Institute (San Francisco, CA, USA) collaborating with other institutes, retrospectively tested samples from 478 subjects drawn at sites with high influenza activity. They collected prospective samples from 1,004 blood donors who called their donation center within three days of donation complaining of influenza-like illness (ILI). The plasma collected on the day of donation for these subjects was tested.

A number of different influenza RNA detection assays were evaluated prior to testing donor samples, all of which were previously shown to detect commonly circulating contemporary influenza viruses. The MGB Alert system (Epoch Biosciences; Bothell, WA, USA) uses RNA extraction followed by RT-PCR. The Prodesse ProFlu-1 assay (Gen-Probe, San Diego, CA, USA) uses RNA extraction followed by a TaqMan-based, real-time RT-PCR amplification targeting the influenza A matrix gene. Transcription-mediated amplification, also from Gen-Probe, uses a target-capture probe for influenza A matrix gene during RNA extraction followed by isothermal amplification using bacteriophage T7 RNA polymerase and Moloney murine leukemia virus reverse transcriptase. The assays were validated on spiked samples and an animal model.

Of the repository samples, two of 478 plasma samples were initially reactive, but were not repeat reactive by influenza TMA. Of blood donors reporting ILI symptoms after donation, only one of 1,004 samples was TMA initially reactive, but was not repeat reactive, while all samples were nonreactive by RT-PCR testing. The authors reported that they failed to detect influenza A viremia using very sensitive tests in blood samples from donors collected during periods of high influenza transmission in the community, with the majority of the tested donors reporting symptoms of influenza-like illness. The preponderance of evidence from this and other studies thus suggests that influenza viremia is at most an exceedingly rare event in blood donors, who are healthy at the time of donation, and that influenza viremia only occurs in subjects with moderate to severe disease. The study was published on March 15, 2012, in the Journal of Infectious Diseases.

Related Links:

Blood Systems Research Institute
Epoch Biosciences
Gen-Probe


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Lab Sample Rotator
H5600 Revolver
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.